سعر اوليبتينا 12.5مجم 30 اقراص 2022

Oliptina 12.5 mg film-coated tablets (alogliptin, a DPP-4 inhibitor) by Rameda for type 2 diabetes; 30 tablets (3 strips) per pack.

• Adults with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose-lowering medicinal products including insulin, when these with diet and exercise do not provide adequate control.Population: Adults >=18 yearsEuropean Medicines Agency (EMA)

• Common: upper respiratory tract infection, nasopharyngitis, hypoglycaemia; headache was the most common adverse reaction with 25 mg.International label, same formulation · European Medicines Agency (EMA)

• Hypersensitivity to alogliptin or excipients, or history of serious hypersensitivity (anaphylaxis, angioedema) to any DPP-4 inhibitor.International label, same formulation · European Medicines Agency (EMA)

• Not for type 1 diabetes or diabetic ketoacidosis; hypoglycaemia risk with a sulphonylurea, insulin or metformin + thiazolidinedione.International label, same formulation · European Medicines Agency (EMA)
• Acute pancreatitis: discontinue if suspected and do not restart if confirmed; caution with a history of pancreatitis.International label, same formulation · European Medicines Agency (EMA)
• Hypersensitivity reactions (anaphylaxis, angioedema, SJS), post-marketing hepatic dysfunction, bullous pemphigoid; caution in NYHA III-IV heart failure.International label, same formulation · European Medicines Agency (EMA)

• CYP450 inhibitors/substrates, warfarin, metformin, pioglitazone, glyburidePrimarily renally excreted with negligible CYP metabolism; no clinically relevant pharmacokinetic interactions shown with CYP inhibitors, warfarin (no INR effect), metformin, pioglitazone or glyburide.European Medicines Agency (EMA)

• No data in pregnant women; animal studies show no harmful effects; as a precaution avoid use during pregnancy.International label, same formulation · European Medicines Agency (EMA)
• Unknown whether excreted in human milk (excreted in animal milk); a risk to the suckling child cannot be excluded.International label, same formulation · European Medicines Agency (EMA)

• Alogliptin: Selective DPP-4 inhibitor that raises active incretin levels, enhancing glucose-dependent insulin secretion and lowering glucagon.